共 32 条
Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis
被引:107
作者:
Saouaf, Sandra J.
[1
]
Li, Bin
[1
]
Zhang, Geng
[1
]
Shen, Yuan
[1
]
Furuuchi, Narumi
[1
]
Hancock, Wayne W.
[1
,2
]
Greene, Mark I.
[1
]
机构:
[1] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA
关键词:
T cell;
Suppression;
Autoimmunity;
Rheumatoid arthritis;
RHEUMATOID-ARTHRITIS;
FOXP3;
TRICHOSTATIN;
EXPRESSION;
ACETYLATION;
SUPPRESSION;
MODULATION;
DEPLETION;
STRATEGY;
THERAPY;
D O I:
10.1016/j.yexmp.2009.06.003
中图分类号:
R36 [病理学];
学科分类号:
100104 ;
摘要:
Collagen-induced arthritis (CIA) is an established mouse model of disease with hallmarks of clinical rheumatoid arthritis. Histone/protein deacetylase inhibitors (HDACi) are known to inhibit the pathogenesis of CIA and other models of autoimmune disease, although the mechanisms responsible are unclear. Regulatory T cell (Treg) function is defective in rheumatoid arthritis. FOXP3 proteins in Tregs are present in a dynamic protein complex containing histone acetyltransferase and HDAC enzymes, and FOXP3 itself is acetylated on lysine residues. We therefore investigated the effects of HDACi therapy on regulatory T cell function in the CIA model. Administration of an HDACi, valproic acid (VPA), significantly decreased disease incidence (p<0.005) and severity (p<0.03) in CIA. In addition, VPA treatment increased both the suppressive function of CD4(+)CD25(+) Tregs (p<0.04) and the numbers of CD25(+)FOXP3(+) Tregs in vivo. Hence, clinically approved HDACi such as VPA may limit autoimmune disease in vivo through effects on the production and function of FOXP3(+) Treg cells. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:99 / 104
页数:6
相关论文